Research To Practice | Oncology Videos Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Nov 13, 2025
Dr. Matthew Lunning is a hematologist specializing in CAR T-cell therapy and bispecific antibodies, while Dr. Sonali M. Smith focuses on lymphoma research and treatment innovations. They discuss the complexities of logistic challenges and early referral strategies for CAR T therapies in high-risk diffuse large B-cell lymphoma (DLBCL). The conversation also highlights the effectiveness of novel agents like epcoritamab and the importance of managing toxicities. They delve into evolving treatment protocols, including the sequence of using bispecifics before CAR T for optimal outcomes.
AI Snips
Chapters
Transcript
Episode notes
Match CAR T Choice To Patient And Logistics
- Choose CAR T product based on logistics, patient age, and disease aggressiveness.
- Prefer lisocabtagene maraleucel for older patients, axi-cel for younger or very aggressive disease, with tisa-cel in between.
Refer Early And Plan For Patient Logistics
- Refer eligible patients early and discuss CAR T as an option rather than assuming they'll be ineligible.
- Address logistical barriers (travel, caregiving, time away) and provide community support for safe return after therapy.
Acute Toxicities Are Early; Chronic Issues Come Later
- Acute CRS and ICANS cluster in the early weeks after CAR T and are now manageable with early steroid strategies.
- Chronic issues (hypogammaglobulinemia, cytopenias) emerge later and need long-term planning.